Fracture rates by medication type in attention-deficit/hyperactive disorder.

Autor: Sidrak JP; School of Medicine, University of Colorado, Aurora, CO, United States., Blaakman SR; University of Rochester, Rochester, NY, United States., Hale EW; School of Medicine, University of Colorado, Aurora, CO, United States.
Jazyk: angličtina
Zdroj: Frontiers in surgery [Front Surg] 2023 Feb 15; Vol. 10, pp. 973266. Date of Electronic Publication: 2023 Feb 15 (Print Publication: 2023).
DOI: 10.3389/fsurg.2023.973266
Abstrakt: Background: ADHD is a condition with extensively researched increased risks of psychiatric disorders, traumatic injury, impulsivity, and delayed response times.
Objectives: To analyze the incidences of fractures in patients with ADHD on various medication regimens.
Methods: Using the TriNetX database, we created seven patient cohorts, all of age under 25, based on medication types commonly used for ADHD. The cohorts we created were: no medication use, exclusive use of a -phenidate class stimulant, exclusive use of an amphetamine class stimulant, nonexclusive use of formations of either stimulant, exclusive use of non-stimulant medications approved for ADHD, nonexclusive use, and no medications. We then examined rates while controlling for age, sex, race, and ethnicity.
Results: The comparison of ADHD to neurotypical individuals revealed an increased risk for all fracture types. For the controlled analysis, all but one cohort had significant differences in each fracture type compared to the baseline cohort of ADHD patients without any medication use. Patients in the "phenidate" cohort had an insignificant difference in risk of lower limb fractures. Patients in the "any medication," "-etamine," "stimulant," and "not ADHD" groups all had significant decreased risks for all fracture types, with confidence intervals often overlapping between treatment modalities.
Conclusions: As patients experiment with different medication regimens, providers should be aware of the difference in risk of fracture by medication type. Our results highlight the need for continued research to better discern appropriate medication regimens with the goal of improving overall risk reduction and producing better outcomes for individuals with ADHD.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(© 2023 Sidrak, Blaakman and Hale.)
Databáze: MEDLINE